MedTrace Logo

Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy

NCT00939315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2016-01-26

No results posted yet for this study

Summary

The aim of this study is to establish the diagnostic value of O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) PET-CT, \[18F\]-fluorocholine (FCH) and magnetic resonance imaging (MRI) combined with magnetic resonance spectroscopy (MRS) in patients with suspected cerebral glioma using neuronavigated biopsies with histopathological analysis as reference.

Conditions

Sponsors & Collaborators

  • Lionel Perrier Foundation (Montreux, Switzerland)

    collaborator UNKNOWN

  • University of Lausanne Hospitals

    lead OTHER

Principal Investigators

  • John O Prior, PhD MD · Centre Hospitalier Universitaire Vaudois and University of Lausanne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939315 on ClinicalTrials.gov